Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity. A randomized clinical trial
暂无分享，去创建一个
N. Halama | L. Bullinger | M. Addo | F. Herth | C. Denkinger | U. Merle | J. Krisam | O. Witzke | M. Vehreschild | P. Tepasse | B. Hertenstein | H. Lorenz | M. Souto-Carneiro | O. Hopfer | S. Schmiedel | P. Stelmach | Cengiz Celik | S. Meuer | M. Gaeddert | W. Kern | A. Schmitt | N. Alakel | M. Weigand | C. Nusshag | C. Schimanski | M. Kiehl | A. Morgner | J. Schrezenmeier | M. Wattad | L. Baumann | U. Schaekel | M. Kreuter | A. Leo | J. Stermann | M. Haenel | M. Janssen | J. Gall | S. Weber | M. Bornhaeuser | T. Wolf | T. Pohle | M. Ruhe | H.-G. Kraeusslich | Muel | Phil Tepasse